Want to learn more? Please visit our main website:
www.rockiesventureclub.org
RVC Signature Series: Life Sciences Night
Date: Wednesday, August 27, 2025
Time: 3:00 PM - 7:00 PM
Location: University of Denver - Margery Reed Hall (2306 E Evans Ave, Denver, Colorado, United States)
Life Sciences offer special opportunities for entrepreneurs, angel investors and Venture Capitalists alike. There are huge markets in healthcare and the investment profits at exit is often different and more robust than other industries as large companies often use acquisition as an R&D strategy. For angel and VC investors, life science investments can be one of the most profitable sectors.
Rockies Venture Club, The Colorado Bioscience Association and Innosphere have joined in partnership to present Life Sciences Night, which will showcase investment ready Colorado life sciences startups, a panel discussion from local VCs, and valuable networking opportunities for entrepreneurs, investors, and mentors.
Well you can learn the answers to these questions and more at the Life Sciences Night!
In partnership with
After the conclusion of presentations, all accredited investors in attendance are invited to join the Rockies Venture Club Investor Forum. RVC Investor Forums serve to pool the wisdom, expertise, and capital of many individual angels. At this forum, investors will privately discuss the merits and risks of each venture. There is no requirement to invest and each investor has an opportunity to indicate interest in following or leading a specific deal. Both new and experienced investor members are welcome at forums -- this is the best way to learn hands-on about angel investing!
Website
https://enterotrack.com/
Description
EnteroTrack, based in Aurora, CO, has developed the Esophageal String Test (EST) — the only non-endoscopic method to screen and monitor Eosinophilic Esophagitis (EoE), reducing patient and payer costs by over 80% compared to endoscopic biopsy. With CAP/CLIA lab operations, Medicare and major insurer reimbursements, and 50+ clinics onboarded, the company has grown test volume 10x in the past year. Backed by 5 granted and 18 pending patents, unique antibodies, and over 7 years of clinical trials, EnteroTrack is scaling toward a $4B market, seeking $2.5M to reach $3M ARR and expand its diagnostic pipeline.
https://www.entirelywell.com/
Entirely Well, a Denver-based startup, is a preventive healthcare company developing personal care products to help prevent yeast infections and bacterial vaginosis—conditions that contribute heavily to antibiotic resistance in women. This year alone, over 46 million women in the US will have a yeast infection or BV. 40% of those women will experience recurring infections, requiring antibiotics several times a year.
Our first products include lubricants, wipes, washes, and condoms—two of which are FDA-reviewable Class II medical devices.
https://www.exoculardx.com/
ExOcular is revolutionizing the management of severe eye diseases by measuring biomarkers isolated from exosomes
ExOcular Dx, headquartered in Boulder, develops multiplex exosome-based diagnostics for early detection, prognosis, and treatment monitoring of severe eye diseases—such as diabetic retinopathy and age-related macular degeneration—by analyzing exosomal biomarkers isolated from bodily fluids to revolutionize disease management.
https://gelsanatherapeutics.com/
GelSana, a 2025 MedTech Innovator company, is engineering smart polymer wound dressings that improve wound healing without drugs by reducing inflammation and repelling bacteria, and that are durable and conformable to a wide range of wounds. GelSana is heading to the clinical market with our first product Cleragel which will be registered with the FDA as a 510(k)-exempt medical device. GelSana has secured a total of $5.5M in funding to date, including $3M from investors and $2.5M from grants from NIH, Air Force, and State of Colorado.
https://www.ilerabio.com/
Ilerabio, a Denver-based biopharma startup, develops patent-protected therapies combining pharmaceutical and natural compounds to address metabolic health needs, starting with ILB-500, a first-in-class insulin sensitizer for PCOS, a condition with no FDA-approved treatments. Founded in 2024 by industry veterans with five prior exits, the company targets women’s health and obesity markets with a pipeline focused on effective, well-tolerated, and affordable treatments delivered through strategic partnerships and global licensing.
https://www.jura.health/
Jura Health, based in Lakewood, CO, is creating an AI-enabled platform that combines whole genome sequencing, multilingual genetic counseling, and personalized care plans to cut rare disease diagnosis times from six years to one month. Focused on Medicaid and underserved patients, the platform enables secure data sharing among patients, providers, and researchers, funded through reimbursement. With $45K in early revenue, Colorado Medicaid approval, and Louisiana pending, Jura targets a $69B market with future growth from a genomic data marketplace.
https://www.lumenastra.io/
LumenAstra, a Boulder-based startup, is developing a non-invasive wearable sensor that measures core body temperature below the skin, starting with real-time brain monitoring in high-risk cardiac surgeries to cut mortality by up to 20%. Backed by $3.3M in non-dilutive funding and University of Colorado patents, the company targets ICU, military, sports, and consumer markets, with FDA Class II clearance and a 2026 launch planned.
https://www.mentemedical.com/
Mente, based in Woodland Park, CO, uses custom RFID technology to track the use of individual surgical instruments, creating a unique intraoperative data stream that optimizes instrument trays and improves OR efficiency. Its first product cuts unused instruments by 50%, reducing tray weight, setup time, and reprocessing costs—saving hospitals about $100K per OR annually. With Duke University Hospital as its first customer, $1.85M raised, and $1.5M in grants, Mente is expanding its pipeline to predictive OR tools, including next-instrument suggestions and surgery end-time forecasting, targeting a $900M SAM in surgical efficiency.
https://www.northernmost.ca/
Northernmost Medical Devices, Inc., is a Canadian startup developing machines to preserve and transport donor organs for transplant. Its first product, NoMo™ Kidney Pump, is a next-generation perfusion machine designed to replace the static storage cooler and modernize transplantation logistics. Based in Edmonton, with a planned US hub in Denver, the company is led by the people who designed, built, and commercialized today's market-dominant kidney transporter. They've returned to disrupt the market they created over 20 years ago.
https://orbitgenomics.com/
Orbit Genomics® is redefining precision medicine with OrbiSeq™, the first AI-powered platform that accurately analyzes short tandem repeats—dynamic, stress-responsive DNA sequences that reveal both inherited disease risk and risk acquired from living. Unlike traditional tests focused on static genetic mutations (SNPs), OrbiSeq delivers a personalized, actionable view of health and disease trajectory.
https://www.platforminnovations.com/
https://www.renewrx.health/
RenewRx, based in Denver, CO, is a tech-enabled maternal health platform that integrates personalized nutrition, behavior coaching, and remote monitoring into prenatal care—generating up to $1,000+/month per patient in reimbursable revenue for OB/GYN and MFM practices. Its proprietary IP includes a billing automation engine, PlateCheck AI, and the One Th1ng™ habit-building program, already demonstrating improved outcomes in gestational diabetes and reducing C-section and NICU rates. With a paid pilot turned standard of care at Pediatrix, 100+ patients served, and national expansion underway, RenewRx is scaling in the $30B maternal health market while improving patient support and provider sustainability.
Want to learn more? Please visit our main website: